Pattern Computer Secures Global Patent Protection for AI-Discovered Triple-Negative Breast Cancer Therapy PCI020302
Key Insights
Pattern Computer (search) has secured patents for PCI020302 (search), an investigational cancer (search) therapy targeting triple-negative breast cancer (search), across the United States, Mexico, 17 European Union countries, the United Kingdom, Switzerland, and Australia.
The therapy was identified using Pattern's proprietary Pattern Discovery Engine (search) (PDE (search)) AI platform and represents a multi-drug combination approach designed to address the complexity of TNBC (search) biology.
PCI020302 (search) has demonstrated activity in preclinical animal models in studies conducted by an independent global contract research organization, with patent protection extending through 2040.
Pattern Computer (search) announced expanded global intellectual property protection for its investigational cancer (search) therapy candidate PCI020302 (search), a preclinical-stage oncology asset targeting triple-negative breast cancer (search) (TNBC (search)). The company has secured patents across multiple jurisdictions including the United States, Mexico, Europe, and Australia, with protection extending through 2040.
AI-Driven Drug Discovery Platform
PCI020302 (search) was identified using Pattern's proprietary Pattern Discovery Engine (search) (PDE (search)) platform, which is designed to uncover deep, explainable patterns in complex biological data. The therapy represents a multi-drug combination approach leveraging synergistic interactions between existing drugs to address the complexity of TNBC (search) biology.
The company's PDE (search) platform uses proprietary mathematical techniques in advanced AI that can find complex patterns in very-high-order data that have eluded detection by much larger systems, including large language models (LLMs). This technology enables the discovery of novel therapeutic combinations with strong experimental validation.
Preclinical Validation and Patent Portfolio
PCI020302 (search) has demonstrated activity in preclinical animal models in studies conducted by an independent global contract research organization (CRO). The company has been granted patents in the United States and Mexico covering the composition and method of use for the proprietary combination of existing small molecule drugs.
In Europe, Pattern has secured broad protection with its TNBC (search)-focused patent granted and in force across 17 European Union countries as well as the United Kingdom and Switzerland. In Australia, the corresponding patent application has been accepted and is proceeding toward grant.
Addressing Unmet Medical Need
Triple-negative breast cancer (search) is characterized as an aggressive and difficult-to-treat form of breast cancer (search) that lacks targeted therapies and disproportionately affects younger and underserved populations. PCI020302 (search)'s combination-based therapeutic strategy aims to address this significant unmet medical need through Pattern's AI-driven approach to drug discovery.
"We are excited to expand our global patent footprint for PCI020302 (search) across key international markets," said Mark Anderson, Chair and CEO of Pattern. "These milestones reflect both the strength of our underlying technology and our commitment to developing impactful therapies for patients facing aggressive cancers like TNBC (search). Our growing IP portfolio supports our mission to translate breakthrough discoveries into real-world solutions."
Development Strategy
PCI020302 (search) is part of Pattern's broader oncology pipeline, all derived from its PDE (search) platform. The company continues to pursue partnerships and development pathways to bring these innovations closer to clinical application. The strengthened patent protection supports future development and partnership opportunities as the therapy advances toward potential clinical trials.
Pattern Computer (search) applies its computational platform not only to drug discovery and diagnostics but also to other sectors including extended biotech, climate challenges, materials science, aerospace manufacturing quality control, veterinary medicine, air traffic operations, equity trading, AI regulatory compliance in the EU, and energy services.